Abstract
Health technology assessment (HTA) methods have become an important health policy tool to assess value. Yet recommendations for what constitutes appropriate and reliable evidence and methodologies for assessment of medical devices are still debated because methods to evaluate pharmaceuticals are often, and incorrectly, the starting points for device assessments. The study aims to: (i) propose recommendations on appropriate methodologies to assess the evidence on medical devices, (ii) identify assessment methods that can be used to measure device value, and (iii) suggest key areas for future work. ISPOR's Medical Devices and Diagnostics Special Interest Group conducted a comprehensive search of databases and gray literature on evidence development and value assessment on medical devices. The literature search was supplemented with hand searching from high impact journals in the related field. The ten-person expert working group obtained written comments through multiple rounds of review from internal and external stakeholders. Recommendations were made to encourage and guide future research. Multicriteria decision analysis was identified as a useful approach to assess the value of treatment. Consideration should be given to resource-use measures; valid and reliable functional status questionnaires; and general and disease-specific, health-related, quality-of-life measures in economic evaluations of device use. For future work, best practices for value framework design should take into consideration those factors that influence the value of medical devices. Integration of value-based evidence data in an evidence-generation and -synthesis process is needed to support market access and adoption decisions. Methodological recommendations for measuring value can be challenging when the selection of domains and assessment of value are not device-specific.
Issue Section:
Expert View
References
1.
Drummond
,
M.
,
Jonsson
,
B.
, and
Rutten
,
F.
, 1997
, “
The Role of Economic Evaluation in the Pricing and Reimbursement of Medicines
,” Health Policy
,
40
(3
), pp. 199
–215
.10.1016/S0168-8510(97)00901-92.
Fry
,
R. N.
,
Avey
,
S. G.
, and
Sullivan
,
S. D.
, 2003
, “
The Academy of Managed Care Pharmacy Format for Formulary Submissions: An Evolving Standard—A Foundation for Managed Care Pharmacy Task Force Report
,” Value Health
,
6
(5
), pp. 505
–521
.10.1046/j.1524-4733.2003.65327.x3.
MedTech Europe,
2022, “
The European Medical Technology Industry in Figures, 2014
,”
MedTech Europe
, Brussels, Belgium, accessed Mar. 28, 2022, https://www.medtecheurope.org/wp-content/uploads/2015/12/MEDTECH_FactFigures_ONLINE3.pdf4.
Drummond
,
M.
,
Griffin
,
A.
, and
Tarricone
,
R.
, 2009
, “
Economic Evaluation for Devices and Drugs—Same or Different?
,” Value Health
,
12
(4
), pp. 402
–404
.10.1111/j.1524-4733.2008.00476_1.x5.
European Network for Health Technology Assessment,
2018, “
Therapeutic Medical Devices
,”
European Network for Health Technology Assessment
, Diemen, The Netherlands, accessed Aug. 16, 2018, https://www.eunethta.eu/wp-content/uploads/2018/01/Therapeutic-medical-devices_Guideline_Final-Nov-2015.pdf6.
Porter
,
M. E.
, 2010
, “
What Is Value in Health Care?
,” N. Engl. J. Med.
,
363
(26
), pp. 2477
–2481
.10.1056/NEJMp10110247.
Siebert
,
M.
,
Clauss
,
L. C.
,
Carlisle
,
M.
,
Casteels
,
B.
,
de Jong
,
P.
,
Kreuzer
,
M.
,
Sanghera
,
S.
, 2002
, “
Health Technology Assessment for Medical Devices in Europe. What Must Be Considered
,” Int. J. Technol. Assess Health Care
,
18
(3
), pp. 733
–740
.https://pubmed.ncbi.nlm.nih.gov/12391964/8.
Pham
,
B.
,
Tu
,
H. A.
,
Han
,
D.
,
Pechlivanoglou
,
P.
,
Miller
,
F.
,
Rac
,
V.
,
Chin
,
W.
,
Tricco
,
A. C.
,
Paulden
,
M.
,
Bielecki
,
J.
, and
Krahn
,
M.
, 2014
, “
Early Economic Evaluation of Emerging Health Technologies: Protocol of a Systematic Review
,” Syst. Rev.
,
3
(1
), p. 81
.10.1186/2046-4053-3-819.
Huot
,
L.
,
Decullier
,
E.
,
Maes-Beny
,
K.
, and
Chapuis
,
F. R.
, 2012
, “
Medical Device Assessment: Scientific Evidence Examined by the French National Agency for Health—A Descriptive Study
,” BMC Public Health
,
12
(1
), p. 585
.10.1186/1471-2458-12-58510.
Schreyogg
,
J.
,
Baumler
,
M.
, and
Busse
,
R.
, 2009
, “
Balancing Adoption and Affordability of Medical Devices in Europe
,” Health Policy
,
92
(2–3
), pp. 218
–224
.10.1016/j.healthpol.2009.03.01611.
Tarricone
,
R.
,
Torbica
,
A.
, and
Drummond
,
M.
, 2017
, “
Challenges in the Assessment of Medical Devices: The MedtecHTA Project
,” Health Econ.
,
26
(Suppl. 1
), pp. 5
–12
.10.1002/hec.346912.
Polisena
,
J.
, 2018
, Health Technology Assessment of Medical Devices: The Canadian Experience
,
Springer Singapore
,
Singapore
.13.
MedTech Europe,
2022, “
Taxonomy of Value-Based Access Programs: Funding for Innovation
,”
MedTech Europe
, Brussels, Belgium, accessed Mar. 28, 2022, https://www.medtecheurope.org/wp-content/uploads/2019/05/2020_MTE_Taxonomy-of-Value-Based-Access-Programs.pdf14.
U.S. Centers for Medicare and Medicaid Services, 2019,
“
What Are the Value-Based Programs
?,”
U.S. Centers for Medicare and Medicaid Services
, Baltimore, MD, accessed Oct. 5, 2019, https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Value-Based-Programs/Value-Based-Programs.html15.
Garrison
,
L. P.
, Jr.
,
Towse
,
A.
,
Briggs
,
A.
,
de Pouvourville
,
G.
,
Grueger
,
J.
,
Mohr
,
P. E.
,
Severens
,
J. L.
,
Siviero
,
P.
, and
Sleeper
,
M.
, 2013
, “
Performance-Based Risk-Sharing Arrangements-Good Practices for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force
,” Value Health
,
16
(5
), pp. 703
–719
.10.1016/j.jval.2013.04.01116.
IJzerman
,
M. J.
,
Koffijberg
,
H.
,
Fenwick
,
E.
, and
Krahn
,
M.
, 2017
, “
Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature
,” Pharmacoeconomics
,
35
(7
), pp. 727
–740
.10.1007/s40273-017-0509-117.
Campbell
,
M. J.
, 2000
, “
Cluster Randomized Trials in General (Family) Practice Research
,” Stat. Methods Med. Res.
,
9
(2
), pp. 81
–94
.10.1177/09622802000090020218.
Leung
,
L.
, 2015
, “
Validity, Reliability, and Generalizability in Qualitative Research
,” J. Fam. Med. Primary Care
,
4
(3
), pp. 324
–327
.10.4103/2249-4863.16130619.
GRADE Working Group,
2004
, “
Grading Quality of Evidence and Strength of Recommendations
,” BMJ
,
328
, p. 1490
.10.1136/bmj.328.7454.149020.
Canadian Task Force on the Periodic Health Examination,
1979
, “
The Periodic Health Examination
,” Can. Med. Assoc. J.
,
121
(9
), pp. 1193
–1254
.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1704686/21.
Sackett
,
D. L.
, 1989
, “
Rules of Evidence and Clinical Recommendations on the Use of Antithrombotic Agents
,” Chest
,
95
(2
), pp. 2S
–4S
.10.1378/chest.95.2_Supplement.2S22.
Centre for Evidence-Based Medicine, University of Oxford
, 2018, “
OCEBM Levels of Evidence
,” Centre for Evidence-Based Medicine, University of Oxford, Oxford, UK, accessed Aug. 16, 2018, https://www.cebm.net/2016/05/ocebm-levels-of-evidence/23.
National Health and Medical Research Council, Australian Government
, 2019, “
NHMRC Additional Levels of Evidence and Grades for Recommendations for Developers of Guidelines
,”
National Health and Medical Research Council, Australian Government
, Canberra, Australia, accessed Oct. 15, 2019, https://www.mja.com.au/sites/default/files/NHMRC.levels.of.evidence.2008-09.pdf24.
Rubin
,
D. B.
, 2008
, “
For Objective Causal Inference, Design Trumps Analysis
,” Ann. Appl. Stat.
,
2
(3
), pp. 808
–840
.https://projecteuclid.org/journals/annals-of-applied-statistics/volume-2/issue-3/For-objective-causalinference-design-trumps-analysis/10.1214/08-AOAS187.full25.
Rome
,
B. N.
,
Kramer
,
D. B.
, and
Kesselheim
,
A. S.
, 2014
, “
Approval of High-Risk Medical Devices in the US: Implications for Clinical Cardiology
,” Curr. Cardiol. Rep.
,
16
(6
), p. 489
.10.1007/s11886-014-0489-026.
Yue
,
L. Q.
, 2007
, “
Special Issue on Medical Device Clinical Studies—Guest Editor's Note
,” J. Biopharm. Stat.
,
18
, pp. 1
–3
.10.1080/1054340070166821727.
Zannad
,
F.
,
Stough
,
W. G.
,
Piña
,
I. L.
,
Mehran
,
R.
,
Abraham
,
W. T.
,
Anker
,
S. D.
,
De Ferrari
,
G. M.
, 2014
, “
Current Challenges for Clinical Trials of Cardiovascular Medical Devices
,” Int. J. Cardiol.
,
175
(1
), pp. 30
–37
.10.1016/j.ijcard.2014.05.02128.
Faris
,
O.
, and
Shuren
,
J.
, 2017
, “
An FDA Viewpoint on Unique Considerations for Medical-Device Clinical Trials
,” N. Engl. J. Med.
,
376
(14
), pp. 1350
–1357
.10.1056/NEJMra151259229.
Bernard
,
A.
,
Vaneau
,
M.
,
Fournel
,
I.
,
Galmiche
,
H.
,
Nony
,
P.
, and
Dubernard
,
J. M.
, 2014
, “
Methodological Choices for the Clinical Development of Medical Devices
,” Med. Devices (Auckland)
,
7
, pp. 325
–334
.10.2147/MDER.S6386930.
Kennedy-Martin
,
T.
,
Curtis
,
S.
,
Faries
,
D.
,
Robinson
,
S.
, and
Johnston
,
J.
, 2015
, “
A Literature Review on the Representativeness of Randomized Controlled Trial Samples and Implications for the External Validity of Trial Results
,” Trials
,
16
(1
), p. 495
.10.1186/s13063-015-1023-431.
Tarricone
,
R.
,
Torbica
,
A.
,
Ferré
,
F.
, and
Drummond
,
M.
, 2014
, “
Generating Appropriate Clinical Data for Value Assessment of Medical Devices: What Role Does Regulation Play?
,” Expert Rev. Pharmacoecon. Outcomes Res.
,
14
(5
), pp. 707
–718
.10.1586/14737167.2014.95023332.
George
,
C. J.
,
Baim
,
D. S.
,
Brinker
,
J. A.
,
Fischman
,
D. L.
,
Goldberg
,
S.
,
Holubkov
,
R.
,
Kennard
,
E. D.
,
Veltri
,
L.
, and
Detre
,
K. M.
, 1998
, “
One-Year Follow-Up of the Stent Restenosis (STRESS I) Study
,” Am. J. Cardiol.
,
81
(7
), pp. 860
–865
.10.1016/S0002-9149(98)00004-633.
Macaya
,
C.
,
Serruys
,
P. W.
,
Ruygrok
,
P.
,
Suryapranata
,
H.
,
Mast
,
G.
,
Klugmann
,
S.
,
Urban
,
P.
, 1996
, “
Continued Benefit of Coronary Stenting Versus Balloon Angioplasty: One-Year Clinical Follow-Up of Benestent Trial
,” J. Am. Coll. Cardiol.
,
27
(2
), pp. 255
–261
.10.1016/0735-1097(95)00473-434.
Webb
,
J. G.
,
Carere
,
R. G.
,
Virmani
,
R.
,
Baim
,
D.
,
Teirstein
,
P. S.
,
Whitlow
,
P.
,
McQueen
,
C.
, 1999
, “
Retrieval and Analysis of Particulate Debris After Saphenous Vein Graft Intervention
,” J. Am. Coll. Cardiol.
,
34
(2
), pp. 468
–475
.10.1016/S0735-1097(99)00196-535.
Dreyer
,
N. A.
,
Tunis
,
S. R.
,
Berger
,
M.
,
Ollendorf
,
D.
,
Mattox
,
P.
, and
Gliklich
,
R.
, 2010
, “
Why Observational Studies Should Be Among the Tools Used in Comparative Effectiveness Research
,” Health Aff. (Millwood)
,
29
(10
), pp. 1818
–1825
.10.1377/hlthaff.2010.066636.
U.S. Food and Drug Administration,
2018, “
Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices: Guidance for Industry and Food and Drug Administration Staff
,”
U.S. Food and Drug Administration
, Silver Spring, MD, accessed Aug. 17, 2018, https://www.fda.gov/media/99447/download37.
Shuren
,
J.
, and
Zuckerman
,
B.
, 2019
, “
How Creative FDA Regulation Led to First-in-the-World Approval of a Cutting-Edge Heart Valve
,”
Medical Design and Outsourcing
, accessed Oct. 4, 2019, https://www.medicaldesignandoutsourcing.com/creative-fda-regulation-led-first-world-approval-cutting-edge-heart-valve/38.
Benson
,
K.
, and
Hartz
,
A. J.
, 2000
, “
A Comparison of Observational Studies and Randomized, Controlled Trials
,” Am. J. Ophthalmol.
,
130
(5
), p. 688
.10.1016/S0002-9394(00)00754-639.
Concato
,
J.
,
Shah
,
N.
, and
Horwitz
,
R. I.
, 2000
, “
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
,” N. Engl. J. Med.
,
342
(25
), pp. 1887
–1892
.10.1056/NEJM20000622342250740.
Abrishami
,
P.
,
Boer
,
A.
, and
Horstman
,
K.
, 2015
, “
How Can We Assess the Value of Complex Medical Innovations in Practice?
,” Expert Rev. Pharmacoecon. Outcomes Res.
,
15
(3
), pp. 369
–371
.10.1586/14737167.2015.103783441.
Tarricone
,
R.
,
Boscolo
,
P. R.
, and
Armeni
,
P.
, 2016
, “
What Type of Clinical Evidence Is Needed to Assess Medical Devices?
,” Eur. Respir. Rev.
,
25
(141
), pp. 259
–265
.10.1183/16000617.0016-201642.
U.S. Food and Drug Administration,
2019, “
Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry and Food and Drug Administration Staff
,”
U.S. Food and Drug Administration
, Silver Spring, MD, accessed Oct. 15, 2019, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postmarket-surveillance-under-section-522-federal-food-drug-and-cosmetic-act43.
U.S. Food and Drug Administration
, 2019, “
Consideration of Uncertainty in Making Benefit-Risk Determinations in Medical Device Premarket Approvals, De Novo Classifications, and Humanitarian Device Exemptions
,”
U.S. Food and Drug Administration
, Silver Spring, MD, accessed Oct. 4, 2019, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/consideration-uncertainty-making-benefit-risk-determinations-medical-device-premarket-approvals-de44.
Jalbert
,
J. J.
,
Ritchey
,
M. E.
,
Mi
,
X.
,
Chen
,
C. Y.
,
Hammill
,
B. G.
,
Curtis
,
L. H.
, and
Setoguchi
,
S.
, 2014
, “
Methodological Considerations in Observational Comparative Effectiveness Research for Implantable Medical Devices: An Epidemiologic Perspective
,” Am. J. Epidemiol.
,
180
(9
), pp. 949
–958
.10.1093/aje/kwu20645.
Price
,
D.
,
Graham
,
C.
,
Parkin
,
C. G.
, and
Peyser
,
T. A.
, 2016
, “
Are Systematic Reviews and Meta-Analyses Appropriate Tools for Assessing Evolving Medical Device Technologies?
,” J. Diabetes Sci. Technol.
,
10
(2
), pp. 439
–446
.10.1177/193229681560786346.
Taylor
,
R. S.
, and
Iglesias
,
C. P.
, 2009
, “
Assessing the Clinical and Cost-Effectiveness of Medical Devices and Drugs: Are They That Different?
,” Value Health
,
12
(4
), pp. 404
–406
.10.1111/j.1524-4733.2008.00476_2.x47.
Tarricone
,
R.
, and
Drummond
,
M.
, 2011
, “
Challenges in the Clinical and Economic Evaluation of Medical Devices: The Case of Transcatheter Aortic Valve Implantation
,” J. Med. Mark.
,
11
(3
), pp. 221
–229
.10.1177/174579041141224248.
Lamph
,
S.
, 2012
, “
Regulation of Medical Devices Outside the European Union
,” J. R. Soc. Med.
,
105
(Suppl. 1
), pp. 12
–21
.10.1258/jrsm.2012.12003749.
Lumenta
,
D. B.
, and
Cooter
,
R. D.
, 2015
, “
Medical Device Registries for Breast Implants—Where To?
,” Saf. Health
,
1
(1
), p. 4
.10.1186/2056-5917-1-450.
U.S. Food and Drug Administration
, 2019, “
Unique Device Identification System
,”
U.S. Food and Drug Administration
, Silver Spring, MD, accessed Oct. 2, 2019, https://www.federalregister.gov/documents/2013/09/24/2013-23059/unique-device-identification-system51.
Segal
,
C.
,
Holve
,
E.
, and
Sabharwal
,
R.
, 2022
, “
Collecting and Using Patient-Reported Outcomes (PRO) for Comparative Effectiveness Research (CER) and Patient-Centered Outcomes Research (PCOR): Challenges and Opportunities. Issue Briefs and Reports. Paper 10
,” EDM Forum, accessed Mar. 28, 2022, https://academyhealth.org/sites/default/files/Collecting%20and%20Using%20PRO%20for%20CER%20and%20PCOR.pdf52.
U.S. Food and Drug Administration
, 2019, “
Value and Use of Patient-Reported Outcomes (PROs) in Assessing Effects of Medical Devices: CDRH Strategic Priorities 2016-2017
,”
U.S. Food and Drug Administration
, Silver Spring, MD, accessed Oct. 4, 2019, https://www.fda.gov/media/109626/download53.
Reynolds
,
I. S.
,
Rising
,
J. P.
,
Coukell
,
A. J.
,
Paulson
,
K. H.
, and
Redberg
,
R. F.
, 2014
, “
Assessing the Safety and Effectiveness of Devices After U.S. Food and Drug Administration Approval: FDA-Mandated Postapproval Studies
,” JAMA Intern. Med.
,
174
(11
), pp. 1773
–1779
.10.1001/jamainternmed.2014.419454.
International Medical Device Regulator Forum, 2018, “
Patient Registry: Essential Principles
,”
International Medical Device Regulator Forum
, accessed Aug. 16, 2018, http://www.imdrf.org/docs/imdrf/final/consultations/imdrf-cons-essential-principles-151124.pdf55.
Tcheng
,
J. E.
,
Crowley
,
J.
,
Tomes
,
M.
,
Reed
,
T. L.
,
Dudas
,
J. M.
,
Thompson
,
K. P.
,
Garratt
,
K. N.
, and
Drozda
,
J. P.
, Jr.
, and MDEpiNet UDI Demonstration Expert Workgroup,
2014
, “
Unique Device Identifiers for Coronary Stent Postmarket Surveillance and Research: A Report From the Food and Drug Administration Medical Device Epidemiology Network Unique Device Identifier Demonstration
,” Am. Heart J.
,
168
(4
), pp. 405
–413.e2.
10.1016/j.ahj.2014.07.00156.
Ho
,
M. P.
,
Gonzalez
,
J. M.
,
Lerner
,
H. P.
,
Neuland
,
C. Y.
,
Whang
,
J. M.
,
McMurry-Heath
,
M.
,
Hauber
,
A. B.
, and
Irony
,
T.
, 2015
, “
Incorporating Patient-Preference Evidence Into Regulatory Decision Making
,” Surg. Endosc.
,
29
(10
), pp. 2984
–2993
.10.1007/s00464-014-4044-257.
Carroll
,
J. D.
,
Edwards
,
F. H.
,
Marinac-Dabic
,
D.
,
Brindis
,
R. G.
,
Grover
,
F. L.
,
Peterson
,
E. D.
,
Tuzcu
,
E. M.
, 2013
, “
The STS-ACC Transcatheter Valve Therapy National Registry: A New Partnership and Infrastructure for the Introduction and Surveillance of Medical Devices and Therapies
,” J. Am. Coll. Cardiol.
,
62
(11
), pp. 1026
–1034
.10.1016/j.jacc.2013.03.06058.
Dawisha
,
S. M.
, and
Kline Leidy
,
N.
, 2011
, “
Patient Reported Outcomes in Decision Making and Communication
,” Therapeutic and Diagnostic Device Outcomes Research
,
S. J.
Ackerman
,
M.
Dix Smith
,
J.
Ehreth
,
R.
Eldessouki
, and
E.
Sullivan
, eds.,
International Society for Pharmacoeconomics and Outcomes Research
,
Lawrenceville, NJ
.59.
Miani
,
C.
,
Robin
,
E.
,
Horvath
,
V.
,
Manville
,
C.
,
Cave
,
J.
, and
Chataway
,
J.
, 2014
, “
Health and Healthcare: Assessing the Real World Data Policy Landscape in Europe
,” RAND Health Q.
,
4
(2
), p. 15
.10.13140/RG.2.2.21633.2544660.
Polly
,
D. W.
, 2011
, “
Therapeutic and Diagnostic Device Clinical Outcomes Research Practical Considerations
,” Therapeutic and Diagnostic Device Outcomes Research
,
S. J.
Ackerman
,
M.
Dix Smith
,
J.
Ehreth
,
R.
Eldessouki
, and
E.
Sullivan
, eds.,
International Society for Pharmacoeconomics and Outcomes Research
,
Lawrenceville, NJ
.61.
U.S. Food and Drug Administration
, 2018, “
Adaptive Designs for Medical Device Clinical Studies: Guidance for Industry and Food and Drug Administration Staff
,”
U.S. Food and Drug Administration
, Silver Spring, MD, accessed Aug. 17, 2018, https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm446729.pdf62.
Haute Autorité de Santé
, 2022, “
Medical Device Assessment in France: Assessment Report
,”
Haute Autorité de Santé
, Saint-Denis, France, accessed Mar. 28, 2022, https://www.has-sante.fr/upload/docs/application/pdf/2010-03/guide_dm_gb_050310_2010-03-12_12-45-33_878.pdf63.
Chow
,
S. C.
, and
Chang
,
M.
, 2008
, “
Adaptive Design Methods in Clinical Trials—A Review
,” Orphanet J. Rare Dis.
,
3
(1
), p. 11
.10.1186/1750-1172-3-1164.
Loudon
,
K.
,
Treweek
,
S.
,
Sullivan
,
F.
,
Donnan
,
P.
,
Thorpe
,
K. E.
, and
Zwarenstein
,
M.
, 2015
, “
The PRECIS-2 Tool: Designing Trials That Are Fit for Purpose
,” BMJ
,
350
, p. h2147
.10.1136/bmj.h214765.
Saksena
,
S.
,
Epstein
,
A. E.
,
Lazzara
,
R.
,
Maloney
,
J. D.
,
Zipes
,
D. P.
,
Benditt
,
D. G.
,
Camm
,
J.
, 1995
, “
Clinical Investigation of Antiarrhythmic Devices. A Statement for Healthcare Professionals From a Joint Task Force of the North American Society of Pacing and Electrophysiology, the American College of Cardiology, the American Heart Association, and the Working Groups on Arrhythmias and Cardiac Pacing of the European Society of Cardiology
,” J. Am. Coll. Cardiol.
,
25
(5
), pp. 961
–973
.10.1016/0735-1097(94)00567-A66.
Rathi
,
V. K.
,
Krumholz
,
H. M.
,
Masoudi
,
F. A.
, and
Ross
,
J. S.
, 2015
, “
Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011
,” JAMA
,
314
(6
), pp. 604
–612
.10.1001/jama.2015.876167.
U.S. Food and Drug Administration
, 2018, “
Design Considerations for Pivotal Clinical Investigations for Medical Devices: Guidance for Industry, Clinical Investigators, Institutional Review Boards, and Food and Drug Administration Staff
,”
U.S. Food and Drug Administration
, Silver Spring, MD, accessed Aug. 17, 2018, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-considerations-pivotal-clinical-investigations-medical-devices68.
Schnipper
,
L. E.
,
Davidson
,
N. E.
,
Wollins
,
D. S.
,
Blayney
,
D. W.
,
Dicker
,
A. P.
,
Ganz
,
P. A.
,
Hoverman
,
J. R.
, 2016
, “
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
,” J. Clin. Oncol.
,
34
(24
), pp. 2925
–2934
.10.1200/JCO.2016.68.251869.
Deloitte, Advanced Medical Technology Association
, 2022, “
A Framework for Comprehensive Assessment of Medical Technologies: Defining Value in the New Health Care Ecosystem
,”
Deloitte, Advanced Medical Technology Association
, accessed Mar. 28, 2022, https://www.advamed.org/wp-content/uploads/2017/05/advamed-framework-comprehensive-assessment-medical-technologies-june2019.pdf70.
European Network for Health Technology Assessment, 2019,
“
HTA Core Model®
,”
European Network for Health Technology Assessment
, Diemen, The Netherlands, accessed Oct. 4, 2019, https://www.eunethta.eu/hta-core-model71.
Institute for Clinical and Economic Review, 2019, “
ICER Value Assessment Framework
,”
Institute for Clinical and Economic Review
, Boston, MA, accessed Oct. 4, 2019, https://icer-review.org/methodology/icers-methods/icer-value-assessment-framework-2/72.
Platteau
,
P.
,
Laurent
,
E.
,
Albano
,
C.
,
Osmanagaoglu
,
K.
,
Vernaeve
,
V.
,
Tournaye
,
H.
,
Camus
,
M.
,
Van Steirteghem
,
A.
, and
Devroey
,
P.
, 2003
, “
An Open, Randomized Single-Centre Study to Compare the Efficacy and Convenience of Follitropin Beta Administered by a Pen Device With Follitropin Alpha Administered by a Conventional Syringe in Women Undergoing Ovarian Stimulation for IVF/ICSI
,” Hum. Reprod.
,
18
(6
), pp. 1200
–1204
.10.1093/humrep/deg23473.
Dillingham
,
T. R.
,
Pezzin
,
L. E.
,
MacKenzie
,
E. J.
, and
Burgess
,
A. R.
, 2001
, “
Use and Satisfaction With Prosthetic Devices Among Persons With Trauma-Related Amputations: A Long-Term Outcome Study
,” Am. J. Phys. Med. Rehabil.
,
80
(8
), pp. 563
–571
.10.1097/00002060-200108000-0000374.
Liem
,
L.
,
Russo
,
M.
,
Huygen
,
F. J.
,
Van Buyten
,
J. P.
,
Smet
,
I.
,
Verrills
,
P.
,
Cousins
,
M.
, 2013
, “
A Multicenter, Prospective Trial to Assess the Safety and Performance of the Spinal Modulation Dorsal Root Ganglion Neurostimulator System in the Treatment of Chronic Pain
,” Neuromodulation
,
16
(5
), pp. 471
–482
.10.1111/ner.1207275.
Earls
,
J. P.
,
Berman
,
E. L.
,
Urban
,
B. A.
,
Curry
,
C. A.
,
Lane
,
J. L.
,
Jennings
,
R. S.
,
McCulloch
,
C. C.
,
Hsieh
,
J.
, and
Londt
,
J. H.
, 2008
, “
Prospectively Gated Transverse Coronary CT Angiography Versus Retrospectively Gated Helical Technique: Improved Image Quality and Reduced Radiation Dose
,” Radiology
,
246
(3
), pp. 742
–753
.10.1148/radiol.246307098976.
Gray
,
D. T.
,
Hollingworth
,
W.
,
Onwudiwe
,
N.
, and
Jarvik
,
J. G.
, 2008
, “
Costs and State-Specific Rates of Thoracic and Lumbar Vertebroplasty, 2001-2005
,” Spine
,
33
(17
), pp. 1905
–1912
.10.1097/BRS.0b013e31817bb0a477.
Min
,
J. K.
,
Gilmore
,
A.
,
Budoff
,
M. J.
,
Berman
,
D. S.
, and
O'Day
,
K.
, 2010
, “
Cost-Effectiveness of Coronary CT Angiography Versus Myocardial Perfusion SPECT for Evaluation of Patients With Chest Pain and No Known Coronary Artery Disease
,” Radiology
,
254
(3
), pp. 801
–808
.10.1148/radiol.0909034978.
De Cock
,
E.
,
Sapoval
,
M.
,
Julia
,
P.
,
de Lissovoy
,
G.
, and
Lopes
,
S.
, 2013
, “
A Budget Impact Model for Paclitaxel-Eluting Stent in Femoropopliteal Disease in France
,” Cardiovasc. Interventional Radiol.
,
36
(2
), pp. 362
–370
.10.1007/s00270-012-0494-x79.
den Boer
,
K. T.
,
Straatsburg
,
I. H.
,
Schellinger
,
A. V.
,
de Wit
,
L. T.
,
Dankelman
,
J.
, and
Gouma
,
D. J.
, 1999
, “
Quantitative Analysis of the Functionality and Efficiency of Three Surgical Dissection Techniques: A Time-Motion Analysis
,” J. Laparoendosc. Adv. Surg. Tech. A
,
9
(5
), pp. 389
–395
.10.1089/lap.1999.9.38980.
Kok
,
M. M.
,
Weernink
,
M. G. M.
,
von Birgelen
,
C.
,
Fens
,
A.
,
van der Heijden
,
L. C.
, and
van Til
,
J. A.
, 2018
, “
Patient Preference for Radial Versus Femoral Vascular Access for Elective Coronary Procedures: The PREVAS Study
,” Cathet. Cardiovasc. Interventions
,
91
(1
), pp. 17
–24
.10.1002/ccd.2703981.
Neaman
,
K. C.
,
Albert
,
M.
, and
Hammond
,
D. C.
, 2011
, “
Rupture Rate and Patterns of Shell Failure With the McGhan Style 153 Double-Lumen Breast Implant
,” Plast. Reconstr. Surg.
,
127
(1
), pp. 47
–53
.10.1097/PRS.0b013e3181fad24882.
Ginsburg
,
G.
, 2005
, “
Human Factors Engineering: A Tool for Medical Device Evaluation in Hospital Procurement Decision-Making
,” J. Biomed. Inf.
,
38
(3
), pp. 213
–219
.10.1016/j.jbi.2004.11.00883.
Wong
,
S. C.
,
Bachinsky
,
W.
,
Cambier
,
P.
,
Stoler
,
R.
,
Aji
,
J.
,
Rogers
,
J. H.
,
Hermiller
,
J.
, 2009
, “
A Randomized Comparison of a Novel Bioabsorbable Vascular Closure Device Versus Manual Compression in the Achievement of Hemostasis After Percutaneous Femoral Procedures: The ECLIPSE (Ensure's Vascular Closure Device Speeds Hemostasis Trial)
,” JACC: Cardiovasc. Interventions
,
2
(8
), pp. 785
–793
.10.1016/j.jcin.2009.06.00684.
Ivlev
,
I.
,
Vacek
,
J.
, and
Kneppo
,
P.
, 2015
, “
Multi-Criteria Decision Analysis for Supporting the Selection of Medical Devices Under Uncertainty
,” Eur. J. Oper. Res.
,
247
(1
), pp. 216
–228
.10.1016/j.ejor.2015.05.07585.
Boston Consulting Group, MedTech Europe,
2019, “
Procurement: The Unexpected Driver of Value-Based Health Care
,”
Boston Consulting Group, MedTech Europe
, Boston, MA, accessed Oct. 3, 2019, https://www.medtecheurope.org/wp-content/uploads/2017/10/2017_MTE_BCG-VBHC-Procurement.pdf86.
Sanders
,
G. D.
,
Neumann
,
P. J.
,
Basu
,
A.
,
Brock
,
D. W.
,
Feeny
,
D.
,
Krahn
,
M.
,
Kuntz
,
K. M.
, 2016
, “
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-Effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine
,” JAMA
,
316
(10
), pp. 1093
–1103
.10.1001/jama.2016.12195Copyright © 2022 by ASME
You do not currently have access to this content.
